Lilly/Daiichi On Track For Prasugrel NDA By Year End, Despite Mixed Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Benefits of the anticlotting drug “clearly outweigh the risks” for most patients, Lilly’s Paul says at R&D day.
You may also be interested in...
Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market
With more than $5 billion operating cash flow, firm is looking for promising in-licensing candidates, CEO Lechleiter says.
Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market
With more than $5 billion operating cash flow, firm is looking for promising in-licensing candidates, CEO Lechleiter says.
Novo Nordisk Halts Development Of AERx, Its Phase III Fast-Acting Inhaled Insulin Product
Lilly/Alkermes' AIR and MannKind's Technosphere Insulin System still aim for market where Exubera failed.